Switch theme
Sign up to access all valuation multiples
COSMOS Pharmaceutical Corp manages retail drugstores in Japan. The company places a emphasis on convenience regarding its product selection, which includes medical products, health and beauty aids, personal-care items, discount cosmetics, household items, food and beverages, greeting cards, seasonal merchandise, alcoholic beverages, tobacco, insect repellent, and miscellaneous everyday consumables. The majority of the company’s revenue is derived from common grocery sales. Cosmos also operates a private grocery brand called ON 365.
1983
17.7K+
LTM Revenue $7.0B
LTM EBITDA $432M
$4.8B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
COSMOS Pharmaceutical has a last 12-month revenue (LTM) of $7.0B and a last 12-month EBITDA of $432M.
In the most recent fiscal year, COSMOS Pharmaceutical achieved revenue of $6.6B and an EBITDA of $369M.
COSMOS Pharmaceutical expects next 12-month revenue of XXX and NTM EBITDA of XXX
See COSMOS Pharmaceutical valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $7.0B | XXX | $6.6B | XXX | XXX | XXX |
| Gross Profit | $1.5B | XXX | $1.3B | XXX | XXX | XXX |
| Gross Margin | 21% | XXX | 20% | XXX | XXX | XXX |
| EBITDA | $432M | XXX | $369M | XXX | XXX | XXX |
| EBITDA Margin | 6% | XXX | 6% | XXX | XXX | XXX |
| EBIT | $279M | XXX | $216M | XXX | XXX | XXX |
| EBIT Margin | 4% | XXX | 3% | XXX | XXX | XXX |
| Net Profit | $210M | XXX | $168M | XXX | XXX | XXX |
| Net Margin | 3% | XXX | 3% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, COSMOS Pharmaceutical's stock price is JPY 8832 (or $61).
COSMOS Pharmaceutical has current market cap of JPY 700B (or $4.8B), and EV of JPY 706B (or $4.8B).
See COSMOS Pharmaceutical trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $4.8B | $4.8B | XXX | XXX | XXX | XXX | $2.65 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, COSMOS Pharmaceutical has market cap of $4.8B and EV of $4.8B.
COSMOS Pharmaceutical's trades at 0.7x EV/Revenue multiple, and 11.9x EV/EBITDA.
Equity research analysts estimate COSMOS Pharmaceutical's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
COSMOS Pharmaceutical has a P/E ratio of 22.9x.
See valuation multiples for COSMOS Pharmaceutical and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $4.8B | XXX | $4.8B | XXX | XXX | XXX |
| EV (current) | $4.8B | XXX | $4.8B | XXX | XXX | XXX |
| EV/Revenue | 0.7x | XXX | 0.7x | XXX | XXX | XXX |
| EV/EBITDA | 11.2x | XXX | 11.9x | XXX | XXX | XXX |
| EV/EBIT | 17.4x | XXX | 19.2x | XXX | XXX | XXX |
| EV/Gross Profit | 3.3x | XXX | n/a | XXX | XXX | XXX |
| P/E | 22.9x | XXX | 25.0x | XXX | XXX | XXX |
| EV/FCF | -340.1x | XXX | -478.4x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialCOSMOS Pharmaceutical's last 12 month revenue growth is 7%
COSMOS Pharmaceutical's revenue per employee in the last FY averaged $0.4M, while opex per employee averaged $0.1M for the same period.
COSMOS Pharmaceutical's rule of 40 is 13% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
COSMOS Pharmaceutical's rule of X is 24% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for COSMOS Pharmaceutical and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 7% | XXX | 7% | XXX | XXX | XXX |
| EBITDA Margin | 6% | XXX | 6% | XXX | XXX | XXX |
| EBITDA Growth | 7% | XXX | 12% | XXX | XXX | XXX |
| Rule of 40 | 13% | XXX | 13% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | 24% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.4M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.1M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 16% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| MedPlus India | XXX | XXX | XXX | XXX | XXX | XXX |
| SC Ropharma | XXX | XXX | XXX | XXX | XXX | XXX |
| Pague Menos | XXX | XXX | XXX | XXX | XXX | XXX |
| Droga Raia | XXX | XXX | XXX | XXX | XXX | XXX |
| Redcare Pharmacy | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
COSMOS Pharmaceutical acquired XXX companies to date.
Last acquisition by COSMOS Pharmaceutical was XXXXXXXX, XXXXX XXXXX XXXXXX . COSMOS Pharmaceutical acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was COSMOS Pharmaceutical founded? | COSMOS Pharmaceutical was founded in 1983. |
| Where is COSMOS Pharmaceutical headquartered? | COSMOS Pharmaceutical is headquartered in Japan. |
| How many employees does COSMOS Pharmaceutical have? | As of today, COSMOS Pharmaceutical has 17.7K+ employees. |
| Is COSMOS Pharmaceutical publicy listed? | Yes, COSMOS Pharmaceutical is a public company listed on TKS. |
| What is the stock symbol of COSMOS Pharmaceutical? | COSMOS Pharmaceutical trades under 3349 ticker. |
| When did COSMOS Pharmaceutical go public? | COSMOS Pharmaceutical went public in 2004. |
| Who are competitors of COSMOS Pharmaceutical? | Similar companies to COSMOS Pharmaceutical include e.g. MedPlus India, SC Ropharma, Pague Menos, Droga Raia. |
| What is the current market cap of COSMOS Pharmaceutical? | COSMOS Pharmaceutical's current market cap is $4.8B |
| What is the current revenue of COSMOS Pharmaceutical? | COSMOS Pharmaceutical's last 12 months revenue is $7.0B. |
| What is the current revenue growth of COSMOS Pharmaceutical? | COSMOS Pharmaceutical revenue growth (NTM/LTM) is 7%. |
| What is the current EV/Revenue multiple of COSMOS Pharmaceutical? | Current revenue multiple of COSMOS Pharmaceutical is 0.7x. |
| Is COSMOS Pharmaceutical profitable? | Yes, COSMOS Pharmaceutical is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of COSMOS Pharmaceutical? | COSMOS Pharmaceutical's last 12 months EBITDA is $432M. |
| What is COSMOS Pharmaceutical's EBITDA margin? | COSMOS Pharmaceutical's last 12 months EBITDA margin is 6%. |
| What is the current EV/EBITDA multiple of COSMOS Pharmaceutical? | Current EBITDA multiple of COSMOS Pharmaceutical is 11.2x. |
| What is the current FCF of COSMOS Pharmaceutical? | COSMOS Pharmaceutical's last 12 months FCF is -$14.2M. |
| What is COSMOS Pharmaceutical's FCF margin? | COSMOS Pharmaceutical's last 12 months FCF margin is 0%. |
| What is the current EV/FCF multiple of COSMOS Pharmaceutical? | Current FCF multiple of COSMOS Pharmaceutical is -340.1x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
